186 related articles for article (PubMed ID: 16140526)
1. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
5. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
8. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
9. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
10. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
11. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
[TBL] [Abstract][Full Text] [Related]
12. Amifostine and curative intent chemoradiation for compromised cancer patients.
Nguyen NP; Levinson B; Dutta S; Karlsson U; Kelly KC; Dowell J; Ludin A; Sallah S
Anticancer Res; 2003; 23(2C):1649-56. PubMed ID: 12820436
[TBL] [Abstract][Full Text] [Related]
13. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
14. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence.
Xunclà M; Barquinero JF; Caballín MR; Craven-Bartle J; Ribas M; de Vega JM; Barrios L
Int J Radiat Biol; 2008 Mar; 84(3):243-51. PubMed ID: 18300025
[TBL] [Abstract][Full Text] [Related]
16. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
17. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.
Andreassen CN; Grau C; Lindegaard JC
Semin Radiat Oncol; 2003 Jan; 13(1):62-72. PubMed ID: 12520465
[TBL] [Abstract][Full Text] [Related]
18. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
[TBL] [Abstract][Full Text] [Related]
20. Established and emerging uses of cytoprotection in head and neck cancer.
Rosenthal DI
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
[No Abstract] [Full Text] [Related]
[Next] [New Search]